Alnylam Pharmaceuticals
NEWS
Theratechnologies’ Trogarzo for HIV, Alnylam’s Lumasiran for advanced primary hyperoxaluria, scPharmaceuticals’ Furoscix for heart failure and more. Here’s a look at the FDA’s October calendar.
There’s a new collaboration in the Parkinson’s disease development space, Cardiff Oncology kicks off a mid-phase study in colorectal cancer and Ocugen published a new review of COVAXIN.
Sarepta Therapeutics and Alnylam Pharmaceuticals have announced the pricing of $1 billion and $900 million in convertible senior notes respectively.
Alnylam announced results Thursday from the APOLLO-B study of patisiran that showed improved functional capacity in (ATTR) amyloidosis patients with cardiomyopathy.
Orbital Therapeutics, co-founded by John Maraganore, launched with the goal of harnessing the full potential of RNA-based therapeutics to tackle diseases in a new and more effective manner.
Alnylam Pharmaceuticals reported positive Phase II results for cemdisiran, an RNA interference (RNAi) drug developed to treat IgA nephropathy.
Alnylam revealed its Phase III APOLLO-B study, which showed that patisiran improves both functional capacity and quality of life in patients with ATTR amyloidosis with cardiomyopathy.
August 1 is RNA Day. BioSpace takes a look at recent breakthroughs in RNA therapeutics, and the vast potential of the “vital biological molecule.”
As the second financial quarter of the year comes to a close, pharma and biotech companies are releasing their financial results. For more information on the top-earning companies, read on.
JOBS
IN THE PRESS